Element Biosciences

How do you benchmark sequencing accuracy without the benchmark itself being biased? 🤔 Reference genomes like GRCh38 were built predominantly from short-read SBS sequencing data. That means errors baked into the reference are invisible, and real biology can get mislabeled as "sequencer error”. A new preprint from the Northwest Genomics Center and collaborators across NIH's SMaHT Network addressed this limitation by developing donor-specific assemblies (DSAs), diploid reference genomes built entirely from long-read + Hi-C data, with zero short-read influence on base calls. That gave them a technology-agnostic yardstick to compare the accuracy of nine short-read platforms. What they found: 📊 After standard quality filtering, the Element AVITI™ showed significantly lower error rates, particularly with UltraQ™ chemistry which had the lowest error of any platform tested. 🔍 In low-complexity regions, where many high-value variants live, AVITI held the lowest SNV and indel error rate. The full breakdown covers the methodology, the figures, and the comparison results. Read it: https://bit.ly/3UdPNok. #AVITI #AVITI24 #Sequencing #Genomics

We're in Houston this week for the Cancer Genomics Consortium Annual Meeting! 🧬 Targeted sequencing is evolving fast, and we're excited to share how Element is pushing it further with Trinity™ on-flow cell hybrid capture on the AVITI24™ platform — bringing more precision and flexibility to your workflow. If you're at the conference, stop by our booth. We'd love to walk you through what makes this approach different and hear what you're working on. 🔬 #CancerResearch #Genomics #AVITI24

⏱️ Turnaround time can be a bottleneck in clinical research, especially when doing targeted sequencing. Our getting started guide covers how 🧬 AVITI24™ and Trinity™ help labs complete target enrichment workflows in as little as one day, without sacrificing the data quality their research demands. Download the guide: https://bit.ly/3PEqidS. #AVITI24 #Sequencing #ClinicalResearch

That's a wrap on ADLM! 🧬 Thanks to everyone who stopped by our booth to see the AVITI24™ in person and learn how we're pairing AVITI24 sequencing with SOPHiA DDM analysis for a true end-to-end clinical research workflow. Great conversations with SOPHiA GENETICS and the community — see you at the next one! #ADLM2026 #AVITI24 #ClinicalResearch

Data from our Element Biosciences AVITI24 platform since we had our upgrade in January. Average number of reads increased from 1.01 Billion to 1.42 Billion. Needless to day that I am very happy with that 😀 [Data from cfDNA libraries ran on Cloudbreak Freestyle High 2x150 flow cells; comparing 18 runs before and 13 runs after upgrade]

During our 5th annual Day of Giving, Element employees and industry colleagues came together across multiple volunteer events to support our local community and make a meaningful impact. 📦 Volunteers partnered with Feeding San Diego to assemble 349 care packages in just two hours, helping provide breakfast and lunch to children throughout San Diego County during the summer months. 🩸 At our blood drive with the San Diego Blood Bank, employees donated 35 units of blood, enough to help save up to 105 lives. Even more inspiring, five team members donated blood for the very first time, and our drive had the largest turnout of the ten blood drives held that day. A huge thank you to everyone who volunteered their time, energy, and expertise. Your commitment to serving our community reflects the spirit of collaboration, curiosity, and impact that drives us every day. #DayofGiving

In June 2022, we shipped our first AVITI™ system. Four years later, our technologies are helping power discoveries around the world, from North America to Europe, Asia, and beyond. While a lot has changed since that first shipment, one thing hasn't: the customers who took a chance on us, partnered with us, and helped shape what Element is today. As we celebrate this milestone, we're grateful for the customers who have stuck with us from the beginning, and those who joined us more recently. Hear from a few of them below. ⬇️ #AVITI #AVITI24 #Sequencing #Multiomics

How can multimodal readouts improve pooled CRISPR screening workflows? 🧬 ⏳ Last chance to register! Our GEN webinar with Tilmann Buerckstuemmer, PhD from Myllia Biotechnology is happening today. Discover how pooled CRISPR screening combined with imaging on the AVITI24™ platform is shedding new light on NF-κB signaling and the regulatory roles of chromatin-modifying complexes. 🔬 Key topics include: Strategies for linking CRISPR perturbations to multiomic readouts to add depth and confidence Identification of chromatin modifying complexes in regulating NF-κB signaling How this approach supports mechanism-of-action studies and enables identification of both positive and negative regulators of signaling pathways Don't wait — secure your spot now: https://bit.ly/4uenMJL. #CRISPRScreening #Genomics #Multiomics #AVITI24

We’re still going strong at EACR and today is your last chance to stop by booth #89! 🎉 Come talk sequencing and multiomics with the Element team. Whether you're working in clinical research, drug discovery, or spatial workflows, our platforms are built to give cancer researchers the data quality and flexibility they need to move science forward. 🔬 We'd love to hear about your research and explore what's possible together. See you at booth #89! 👋 #EACR2026 #Sequencing #Multiomics

We are thrilled to announce our Series E round of financing, which includes $175 million from Samsung Electronics. "This financing represents a powerful vote of confidence in our vision, our technology, and our team's ability to execute. At a time when many life science companies continue to face significant market challenges, the support of both new and existing investors validates the progress we have made in building a differentiated portfolio of products and bringing them successfully to customers." - Molly He, CEO and Co-Founder of Element This new capital directly supports the commercialization and adoption of our growing ecosystem of genomic and multiomic technologies, including AVITI™, VITARI™, upcoming tissue applications on AVITI24™, and AVITI Dx™. Most importantly, it enables us to accelerate our mission of empowering researchers with transformative technologies that advance scientific discovery, support the future of precision medicine, and ultimately improve human health. Learn more: https://bit.ly/4fAEkrI. #AVITI #AVITI24 #VITARI